INmune Bio reports ‘significant’ EEG improvement in patients treated with Xpro

INmune Bio reports significant improvements in electroencephalography, EEG, a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro for four weeks. Patients who received weekly XPro treatment for four weeks had a statistically significant increase in Alpha wave frequency and power. Reduced Alpha power is linked with cognitive decline and the progression of Alzheimer’s Disease. Alpha waves represent synchronized brain network activity that are essential for internal functions like mental arithmetic, short-term and working memory, and visual-spatial mental imagery exercises. “Functional benefits are the true benchmark of a drugs biological efficacy, and these promising findings are part of a larger narrative that’s still unfolding,” stated CJ Barnum, PhD, VP of Neuroscience at INmune Bio. “We are committed to extensive research, drawing from our Phase 2 placebo-controlled trial to substantiate these findings.”